BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amstutz U, Farese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10:931-944. [PMID: 19530960 DOI: 10.2217/pgs.09.28] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 van Kuilenburg ABP, Etienne-grimaldi M, Mahamat A, Meijer J, Laurent-puig P, Olschwang S, Gaub M, Hennekam RCM, Benchimol D, Houry S, Letoublon C, Gilly F, Pezet D, Andre T, Faucheron J, Abderrahim-ferkoune A, Vijzelaar R, Pradere B, Milano G. Frequent intragenic rearrangements of DPYD in colorectal tumours. Pharmacogenomics J 2015;15:211-8. [DOI: 10.1038/tpj.2014.68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Harris M, van Kuilenburg AB, Mead S, Cameron A, Helsby N, George R, Charles BG. Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. European Journal of Pharmaceutical Sciences 2016;81:36-41. [DOI: 10.1016/j.ejps.2015.10.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
3 Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, Schellens JH, Guchelaar HJ. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics 2015;16:1277-86. [PMID: 26265346 DOI: 10.2217/pgs.15.70] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
4 Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, Gariboldi M, Pierotti MA, Di Bartolomeo M, Sottotetti E, Mennitto R, Bossi I, de Braud F, Clementi E, Pietrantonio F. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol 2015;80:581-8. [PMID: 25782327 DOI: 10.1111/bcp.12631] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
5 González-Perera I, Gutiérrez-Nicolás F, Nazco-Casariego GJ, Ramos-Díaz R, Hernández-San Gil R, Pérez-Pérez JA, González García J, González De La Fuente GA. 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798). J Oncol Pharm Pract 2017;23:396-8. [PMID: 27122156 DOI: 10.1177/1078155216647202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103:210-216. [PMID: 29152729 DOI: 10.1002/cpt.911] [Cited by in Crossref: 177] [Cited by in F6Publishing: 153] [Article Influence: 35.4] [Reference Citation Analysis]
7 Khushman M, Patel GK, Hosein PJ, Laurini JA, Cameron D, Clarkson DR, Butler TW, Norden CW, Baliem W, Jones V, Bhadkamkar S, Nelson C, Lee F, Singh AP, Taylor WR. Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. J Gastrointest Oncol 2018;9:416-24. [PMID: 29998006 DOI: 10.21037/jgo.2018.02.03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Schwarzenbach H. Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy. EPMA J 2010;1:485-94. [PMID: 23199090 DOI: 10.1007/s13167-010-0022-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ab Mutalib NS, Md Yusof NF, Abdul SN, Jamal R. Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update. Front Pharmacol 2017;8:736. [PMID: 29075194 DOI: 10.3389/fphar.2017.00736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
10 Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer. 2010;9:224-228. [PMID: 20920994 DOI: 10.3816/ccc.2010.n.033] [Cited by in Crossref: 61] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
11 Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013;108:2505-15. [PMID: 23736036 DOI: 10.1038/bjc.2013.262] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 10.9] [Reference Citation Analysis]
12 Sistonen J, Smith C, Fu YK, Largiadèr CR. A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy. Clin Chim Acta. 2012;414:109-111. [PMID: 22935545 DOI: 10.1016/j.cca.2012.08.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
13 van Kuilenburg AB, Meijer J, Maurer D, Dobritzsch D, Meinsma R, Los M, Knegt LC, Zoetekouw L, Jansen RL, Dezentjé V, van Huis-Tanja LH, van Kampen RJ, Hertz JM, Hennekam RC. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. Biochim Biophys Acta Mol Basis Dis 2017;1863:721-30. [PMID: 28024938 DOI: 10.1016/j.bbadis.2016.12.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
14 Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerbäck C. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clin Biochem. 2010;43:331-334. [PMID: 19822137 DOI: 10.1016/j.clinbiochem.2009.09.024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
15 Emami AH, Sadighi S, Shirkoohi R, Mohagheghi MA. Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal Cancer. Asian Pac J Cancer Prev 2017;18:2803-7. [PMID: 29072417 DOI: 10.22034/APJCP.2017.18.10.2803] [Reference Citation Analysis]
16 Shin J, Kang TS, Cheong HS, Shin HJ, Park HJ, Na HS, Shin HD, Chung MW. Determination of DPYD Enzyme Activity in Korean Population. Therapeutic Drug Monitoring 2015;37:147-51. [DOI: 10.1097/ftd.0000000000000109] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB. Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity. Clin Pharmacol Ther 2017;102:662-70. [PMID: 28295243 DOI: 10.1002/cpt.685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
18 Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol. 2013;71:361-370. [PMID: 23139054 DOI: 10.1007/s00280-012-2018-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
19 Martens FK, Huntjens DW, Rigter T, Bartels M, Bet PM, Cornel MC. DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice. Front Pharmacol 2019;10:1609. [PMID: 32047438 DOI: 10.3389/fphar.2019.01609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Helsby NA, Duley J, Burns KE, Bonnet C, Jeong SH, Brenman E, Barlow P, Sharples K, Porter D, Findlay M. A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. Br J Clin Pharmacol 2020;86:155-64. [PMID: 31658382 DOI: 10.1111/bcp.14153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Diasio RB, Innocenti F, Offer SM. Pharmacogenomic-Guided Therapy in Colorectal Cancer. Clin Pharmacol Ther 2021;110:616-25. [PMID: 34114648 DOI: 10.1002/cpt.2334] [Reference Citation Analysis]
22 Bank PC, Swen JJ, Guchelaar HJ. Pharmacogenetic biomarkers for predicting drug response. Expert Rev Mol Diagn. 2014;14:723-735. [PMID: 24857685 DOI: 10.1586/14737159.2014.923759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
23 Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol. 2017;28:2915-2922. [PMID: 29045513 DOI: 10.1093/annonc/mdx411] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
24 Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74:2545-2554. [PMID: 24648345 DOI: 10.1158/0008-5472.can-13-2482] [Cited by in Crossref: 94] [Cited by in F6Publishing: 40] [Article Influence: 11.8] [Reference Citation Analysis]
25 Cortejoso L, García-González X, García MI, García-Alfonso P, Sanjurjo M, López-Fernández LA. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. Pharmacogenomics 2016;17:979-84. [PMID: 27248859 DOI: 10.2217/pgs-2016-0006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
26 Offer SM, Diasio RB. Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies? J Clin Oncol 2016;34:205-7. [PMID: 26644533 DOI: 10.1200/JCO.2015.64.2546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
27 Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracil -based chemotherapy toxicity. Expert Opin Drug Metab Toxicol 2015;11:811-21. [PMID: 25800061 DOI: 10.1517/17425255.2015.1027684] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
28 Božina N, Bilić I, Ganoci L, Šimičević L, Pleština S, Lešnjaković L, Trkulja V. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. Br J Clin Pharmacol 2021. [PMID: 34780066 DOI: 10.1111/bcp.15144] [Reference Citation Analysis]
29 Wang X, Xie JB, Wu G, Li XL, Han SY. Single nucleotide polymorphisms of ENOSF1 are predictors of therapeutic safety of capecitabine in colorectal cancer. Shijie Huaren Xiaohua Zazhi 2017; 25(35): 3133-3140 [DOI: 10.11569/wcjd.v25.i35.3133] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB. Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol Ther 2017;101:382-90. [PMID: 27727460 DOI: 10.1002/cpt.531] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
31 Daly AK. Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharmacol 2012;63:137-67. [PMID: 22776641 DOI: 10.1016/B978-0-12-398339-8.00004-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
32 Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E, Pietrantonio F. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. Int J Mol Sci 2015;16:8884-95. [PMID: 25906475 DOI: 10.3390/ijms16048884] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
33 Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS One 2017;12:e0175998. [PMID: 28481884 DOI: 10.1371/journal.pone.0175998] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 8.6] [Reference Citation Analysis]
34 Furukawa T, Sasaki T, Ono Y, Kawano F, Takamatsu M, Mori C, Mie T, Yamada Y, Okamoto T, Takeda T, Kasuga A, Matsuyama M, Ozaka M, Takahashi Y, Sasahira N. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Clin J Gastroenterol 2021. [PMID: 34255287 DOI: 10.1007/s12328-021-01480-w] [Reference Citation Analysis]
35 Palmirotta R, Lovero D, Delacour H, Le Roy A, Cremades S, Silvestris F. Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report. Front Oncol 2019;9:139. [PMID: 30915274 DOI: 10.3389/fonc.2019.00139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
36 Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011;12:113-24. [PMID: 21174626 DOI: 10.2217/pgs.10.147] [Cited by in Crossref: 78] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
37 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 2014; 20(29): 9775-9827 [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
38 Hamzic S, Wenger N, Froehlich TK, Joerger M, Aebi S, Largiadèr CR, Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2017;17:319-24. [DOI: 10.1038/tpj.2016.23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Iyer SN, Singhal RS, Hegde MR, Ankala A. Genetic variation in dihydropyrimidine dehydrogenase ( DPYD ) gene in a healthy adult Indian population. Annals of Human Biology 2015;42:97-100. [DOI: 10.3109/03014460.2014.942365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
40 Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther 2013;94:158-66. [PMID: 23588312 DOI: 10.1038/clpt.2013.69] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
41 Crona D, Innocenti F. Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med 2012;6:349-62. [PMID: 22731909 DOI: 10.2217/bmm.12.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader C. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clin Pharmacol Ther 2017;102:796-804. [DOI: 10.1002/cpt.641] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
43 Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics. 2013;14:315-324. [PMID: 23394393 DOI: 10.2217/pgs.12.213] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
44 Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14:1255-1272. [PMID: 23930673 DOI: 10.2217/pgs.13.116] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 10.4] [Reference Citation Analysis]
45 García-González X, Kaczmarczyk B, Abarca-Zabalía J, Thomas F, García-Alfonso P, Robles L, Pachón V, Vaz Á, Salvador-Martín S, Sanjurjo-Sáez M, López-Fernández LA. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. Cancer Chemother Pharmacol 2020;86:45-54. [PMID: 32529295 DOI: 10.1007/s00280-020-04093-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D'Amico M, Fucile C, Marini V, Forzano F, Cassola G, Martelli A, Faravelli F, Di Maria E. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol 2011;68:1355-61. [PMID: 21833589 DOI: 10.1007/s00280-011-1709-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
47 Romiti A, Roberto M, D’antonio C, Onesti CE, Barucca V, Milano A, Gentile G, Lionetto L, Medda E, Mazzuca F, Botticelli A, Falcone R, Simmaco M, Marchetti P. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anti-Cancer Drugs 2016;27:1044-9. [DOI: 10.1097/cad.0000000000000429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
48 Alessandrini M, Chaudhry M, Dodgen TM, Pepper MS. Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS 2016;20:593-603. [PMID: 27643672 DOI: 10.1089/omi.2016.0122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
49 Meulendijks D, Henricks LM, van Kuilenburg ABP, Jacobs BAW, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, Schellens JHM. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemother Pharmacol 2016;78:875-80. [DOI: 10.1007/s00280-016-3137-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
50 Burns KE, Allright D, Porter D, Findlay MP, Helsby NA. A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. Cancer Chemother Pharmacol 2019;84:739-48. [PMID: 31324934 DOI: 10.1007/s00280-019-03904-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, Diasio RB. Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 2018;104:709-18. [PMID: 29327356 DOI: 10.1002/cpt.1020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
52 Hishinuma E, Gutiérrez Rico E, Hiratsuka M. In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase. J Clin Med 2020;9:E2342. [PMID: 32707991 DOI: 10.3390/jcm9082342] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2015;136:730-9. [PMID: 24923815 DOI: 10.1002/ijc.29025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
54 Pesenti C, Gusella M, Sirchia SM, Miozzo M. Germline oncopharmacogenetics, a promising field in cancer therapy. Cell Oncol (Dordr) 2015;38:65-89. [PMID: 25573079 DOI: 10.1007/s13402-014-0214-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
55 Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S. 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251-265. [PMID: 21332317 DOI: 10.2217/pgs.10.167] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
56 Sistonen J, Büchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiadèr CR. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 2014;15:1653-66. [PMID: 25410891 DOI: 10.2217/pgs.14.126] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
57 Lee AM, Diasio RB. Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility. J Clin Oncol 2014;32:989-90. [PMID: 24590640 DOI: 10.1200/JCO.2013.53.4479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
58 Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord J, Toulas C, Chatelut E. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin Pharmacol Ther 2016;99:235-42. [DOI: 10.1002/cpt.210] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
59 Wigle TJ, Tsvetkova EV, Welch SA, Kim RB. DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics. 2019;11. [PMID: 31052357 DOI: 10.3390/pharmaceutics11050199] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
60 van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, Hennekam RC, Mannens MM, Kiechle M, Etienne-Grimaldi MC. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet. 2010;128:529-538. [PMID: 20803296 DOI: 10.1007/s00439-010-0879-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
61 Shin JG, Cheong HS, Kim JY, Kim LH, Han CS, Kim JO, Kim HD, Kim YH, Chung MW, Han SY, Shin HD. Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups. J Korean Med Sci 2013;28:1129-33. [PMID: 23960437 DOI: 10.3346/jkms.2013.28.8.1129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
62 Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011;12:1321-36. [PMID: 21919607 DOI: 10.2217/pgs.11.72] [Cited by in Crossref: 136] [Cited by in F6Publishing: 117] [Article Influence: 13.6] [Reference Citation Analysis]
63 Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr CR. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics 2015;16:1367-77. [DOI: 10.2217/pgs.15.81] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
64 Patel JN, Fuchs CS, Owzar K, Chen Z, McLeod HL. Gastric cancer pharmacogenetics: progress or old tripe? Pharmacogenomics 2013;14:1053-64. [PMID: 23837480 DOI: 10.2217/pgs.13.88] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
65 Palmirotta R, Carella C, Silvestris E, Cives M, Stucci SL, Tucci M, Lovero D, Silvestris F. SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget 2018;9:25355-82. [PMID: 29861877 DOI: 10.18632/oncotarget.25256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
66 Deenen MJ, Henricks LM, Sonke GS, Schellens JH, Meulendijks D. Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia". Tumour Biol 2017;39:1010428317701629. [PMID: 28618970 DOI: 10.1177/1010428317701629] [Reference Citation Analysis]
67 Alcazar-González GA, Calderón-Garcidueñas AL, Garza-Rodríguez ML, Rubio-Hernández G, Escorza-Treviño S, Olano-Martin E, Cerda-Flores RM, Castruita-Avila AL, González-Guerrero JF, le Brun S, Simon-Buela L, Barrera-Saldaña HA. Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer. Pharmacogenomics 2013;14:1583-92. [PMID: 24088129 DOI: 10.2217/pgs.13.83] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
68 Maharjan AS, McMillin GA, Patel GK, Awan S, Taylor WR, Pai S, Frankel AE, Nelson C, Wang B, Hosein PJ, Singh AP, Khushman M. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis. Clin Colorectal Cancer 2019;18:e280-6. [PMID: 31160238 DOI: 10.1016/j.clcc.2019.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zhou Y, Lauschke VM. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. Hum Genet 2021. [PMID: 34652573 DOI: 10.1007/s00439-021-02385-x] [Reference Citation Analysis]
70 Amstutz U, Farese S, Aebi S, Largiadèr CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res. 2008;27:54. [PMID: 18937829 DOI: 10.1186/1756-9966-27-54] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
71 Hodroj K, Barthelemy D, Lega JC, Grenet G, Gagnieu MC, Walter T, Guitton J, Payen-Gay L. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. ESMO Open 2021;6:100125. [PMID: 33895696 DOI: 10.1016/j.esmoop.2021.100125] [Reference Citation Analysis]
72 Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 2016;26:133-7. [PMID: 26658227 DOI: 10.1097/FPC.0000000000000197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
73 Hamzic S, Schärer D, Offer SM, Meulendijks D, Nakas C, Diasio RB, Fontana S, Wehrli M, Schürch S, Amstutz U, Largiadèr CR. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. Br J Clin Pharmacol 2021;87:3234-43. [PMID: 33491253 DOI: 10.1111/bcp.14742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94:640-645. [PMID: 23988873 DOI: 10.1038/clpt.2013.172] [Cited by in Crossref: 218] [Cited by in F6Publishing: 195] [Article Influence: 24.2] [Reference Citation Analysis]
75 Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:1639-50. [PMID: 26603945 DOI: 10.1016/S1470-2045(15)00286-7] [Cited by in Crossref: 166] [Cited by in F6Publishing: 80] [Article Influence: 23.7] [Reference Citation Analysis]
76 Meulendijks D, Rozeman EA, Cats A, Sikorska K, Joerger M, Deenen MJ, Beijnen JH, Schellens JHM. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J 2017;17:441-51. [DOI: 10.1038/tpj.2016.81] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
77 Laface C, Laforgia M, Molinari P, Ugenti I, Gadaleta CD, Porta C, Ranieri G. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers (Basel) 2021;13:3091. [PMID: 34205656 DOI: 10.3390/cancers13123091] [Reference Citation Analysis]
78 Kuilenburg ABPV, Meijer J, Tanck MWT, Dobritzsch D, Zoetekouw L, Dekkers LL, Roelofsen J, Meinsma R, Wymenga M, Kulik W, Büchel B, Hennekam RCM, Largiadèr CR. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochim Biophys Acta 2016;1862:754-62. [PMID: 26804652 DOI: 10.1016/j.bbadis.2016.01.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
79 Zhang C, Liu H, Ma B, Song Y, Gao P, Xu Y, Yu D, Wang Z. The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis. Dis Markers 2017;2017:9202676. [PMID: 28255193 DOI: 10.1155/2017/9202676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
80 Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J. 2019;19:556-563. [PMID: 30723313 DOI: 10.1038/s41397-019-0077-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
81 Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 2013;73:1958-68. [PMID: 23328581 DOI: 10.1158/0008-5472.CAN-12-3858] [Cited by in Crossref: 67] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
82 Brečević L, Rinčić M, Krsnik Ž, Sedmak G, Hamid AB, Kosyakova N, Galić I, Liehr T, Borovečki F. Association of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigma. Transl Neurosci 2015;6:59-86. [PMID: 28123791 DOI: 10.1515/tnsci-2015-0007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
83 van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J 2013;13:389-95. [PMID: 23856855 DOI: 10.1038/tpj.2013.25] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]